Literature DB >> 2571645

T-cell clones with L3T4-positive or Lyt-2-positive phenotypes responding to mutant MHC class II antigen and inducing graft versus host reaction.

H Watanabe1, M Fujiwara, T Mashiko, M Ito.   

Abstract

Two types of T cell clones responding to mutant major histocompatibility class II antigen (Iabm12) were established from spleen cells of C57BL/6 mice: one was L3T4-positive and the other Lyt-2-positive. These two types of clones carried functionally different properties. Lyt-2+ clones were absolutely dependent on exogenous interleukin-2 for their proliferation, whereas some L3T4+ clones secreted interleukin-2 and proliferated autonomously. Both types of clones had cytotoxic activities to bm12 target cells, and Lyt-2+ clones showed stronger activities than L3T4+ clones. Lyt-2+ clones induced induration in situ, whereas the L3T4+ clones induced ulcerative reaction when injected intradermally into mice. Histologically, the L3T4+ clones caused necrosis of the epidermis or upperdermis, while the Lyt-2+ clones induced infiltration of small round cells through the epidermis to the subcutaneous tissues and caused thickening of the epidermis. These characteristic reactivities might be due to a difference in lymphokines produced by each type of T cell subset in response to Iabm12 antigen.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571645     DOI: 10.1111/1523-1747.ep12319888

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  2 in total

1.  Induction of cutaneous graft-versus-host disease by local injection of unprimed T cells.

Authors:  K Kawai; Y Matsumoto; H Watanabe; M Ito; M Fujiwara
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

2.  Phenotypic and functional modulation of T cells in vivo by extrathymic T cells when T cells with MHC class II disparity were injected into athymic nude mice.

Authors:  K Tomiyama; H Watanabe; S Seki; M Ito; T Abo
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.